TScan Therapeutics TCRX Cash Flow Statement (2020-2026)

NASDAQ TCRX
$0.14 -0.01 (-6.67%)
At close: Nov 19, 2026 · 4:00 PM EST
Reported Financials

TScan Therapeutics Quarterly Cash Flow Statement

Periods 26 quarters
Latest Sep 2026
Industry Template General

TScan Therapeutics reported cash from operations of -$27.09M and free cash flow of -$27.13M for the quarter ended Sep 2026, up 16.6% year over year. This cash flow statement covers 26 quarters of results from Jun 2020 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Operating Activities
Net Income
-14.20M-16.16M-15.10M-16.25M-18.72M-22.56M-24.05M-23.00M-19.61M-30.14M-31.66M-29.89M-35.81M-34.13M-36.95M-35.71M-22.98M-28.67M-30.36M-33.09M
Depreciation and DepletionDep. & Depletion
1.14M1.20M1.21M1.25M1.48M1.50M1.30M1.29M1.28M1.25M1.12M1.03M0.71M0.68M0.70M0.77M0.72M0.69M0.70M0.68M
Depreciation, Depletion & Amortization
Amortization of IntangiblesAmort. of Intangibles
0.53M0.48M
Depreciation & Amortization (CF)Dep. & Amort.
1.14M1.20M1.21M1.25M1.48M1.50M1.30M1.29M1.28M1.25M1.12M1.03M0.71M0.68M0.70M0.77M0.72M0.69M0.70M0.68M
Share-based CompensationStock Comp.
0.78M0.98M1.02M1.25M1.30M1.15M1.22M1.34M1.50M1.98M2.33M2.52M2.71M3.41M3.27M3.01M2.01M2.47M2.36M2.08M
Deferred Taxes
68.28M99.59M
Other non-cash itemsOther Non-Cash
0.22M0.21M0.22M-0.01M-1.49M-0.25M-0.19M-1.30M-1.06M-1.17M-0.67M4.19M-4.76M0.12M0.13M
Change in Working Capital
Change in Account PayablesChange Payables
-2.46M0.82M0.41M-1.12M0.41M0.50M0.37M-0.27M-0.64M-0.41M0.40M1.03M0.98M0.56M-0.44M1.93M-5.07M1.05M0.84M-1.88M
Change in Accrued ExpensesChange Accrued Exp.
1.85M-2.80M0.61M1.60M1.32M0.74M0.78M1.02M1.31M-1.60M1.95M0.53M3.66M-5.41M2.67M-1.11M-3.38M0.90M-0.74M5.04M
Change in Other Operating AssetsOther Assets Change
-0.44M2.11M-1.21M1.50M-1.99M1.18M-2.91M0.69M0.05M-0.26M0.02M1.17M-0.39M0.52M-0.04M-0.87M0.90M-0.13M-0.48M-0.47M
Change in Other Operating LiabilitiesOther Liabilities Change
-1.93M-2.07M-2.73M-2.27M-4.01M-3.94M27.16M-3.58M-6.82M-0.35M-0.14M-0.66M0.22M-1.00M-1.89M-2.05M-2.48M-0.97M-1.04M-0.57M
Other Working Capital ChangesOther WC Changes
-0.03M-0.03M-0.03M-0.03M-1.95M-0.06M0.30M0.30M0.39M0.21M0.39M0.39M0.89M1.17M1.19M0.46M0.09M0.02M0.01M0.01M
Cash from OperationsCash from Ops.
-14.38M-20.12M-13.37M-17.00M-16.01M-23.59M-22.02M8.02M-23.77M-29.27M-26.23M-27.92M-27.41M-37.59M-33.27M-32.46M-32.00M-24.28M-27.54M-27.09M
Investing Activities
Capital ExpendituresCapex
2.21M0.53M1.89M0.42M1.38M0.84M0.42M1.42M0.47M0.71M0.86M1.37M0.89M1.53M1.28M1.43M0.17M0.07M0.49M0.04M
Change in Property, Plant and EquipmentChange in PP&E
-2.21M-0.53M-1.89M-0.42M-1.38M-0.84M-0.42M-1.42M-0.47M-0.71M-0.86M-1.37M-0.89M-1.53M-1.28M-1.43M-0.17M-0.07M-0.49M-0.04M
Purchase of InvestmentsInvestments Purchased
17.62M8.78M48.35M136.98M47.33M60.94M26.53M0.00M
Sale and Maturity of InvestmentsInvestments Sold
45.65M15.50M56.00M75.51M76.00M76.25M34.00M15.00M
Other Investing Activities (as filed)Other investing (as filed)
4.44M5.03M0.01M5.03M5.03M5.03M5.03M
Cash from Investing ActivitiesCash from Investing
-2.21M-0.53M-1.89M-0.42M-1.38M-0.84M-0.42M-61.41M1.91M36.16M-33.72M-82.35M27.29M13.53M48.44M32.58M14.83M-0.07M-0.47M-0.04M
Financing Activities
Change in Capital Stock
Common Stock IssuedStock Issued
0.12M0.09M0.03M0.01M0.20M-0.25M0.02M0.26M161.59M1.23M30.38M0.07M
Net Shares Issued and RepurchasedNet Shares Issued
0.12M0.09M0.03M0.01M0.20M-0.25M0.02M0.26M161.59M1.23M30.38M0.07M
Net Preferred Shares Issued and RepurchasedNet Pref. Shares Issued
Net Equity Issued and RepurchasedNet Equity Issued
0.12M0.09M0.03M0.01M0.20M-0.25M0.02M0.26M161.59M1.23M30.38M0.07M
Other financing activities (as filed)
-0.23M-0.09M-0.13M-0.08M
Cash from Financing ActivitiesCash from Financing
0.12M0.09M0.03M29.13M0.11M-0.25M0.02M0.26M161.59M1.23M45.69M-0.53M0.12M0.07M
Additional items
Change in Cash
-16.47M-20.57M-15.23M11.70M-17.28M-24.43M113.23M-53.65M-21.83M7.15M101.65M-109.04M45.57M-24.58M15.29M0.11M-17.10M-24.35M-27.90M-27.12M
Ending Cash Balance
166.44M145.87M130.64M142.34M125.06M100.64M213.87M160.22M138.39M145.54M247.19M138.15M183.72M159.14M174.43M174.54M157.44M133.09M105.19M78.07M
Free Cash FlowFCF
-16.59M-20.66M-15.26M-17.43M-17.39M-24.43M-22.44M6.60M-24.24M-29.97M-27.09M-29.29M-28.30M-39.12M-34.55M-33.89M-32.17M-24.35M-28.03M-27.13M
Net Cash FlowNCF
-16.47M-20.57M-15.23M11.70M-17.28M-24.43M-22.44M-53.65M-21.83M7.15M101.65M-109.04M45.57M-24.58M15.29M0.11M-17.10M-24.35M-28.00M-27.13M
Interest Paid
0.74M0.76M0.76M0.74M0.76M0.75M0.76M0.61M0.57M0.58M0.58M0.58M0.57M0.58M0.58M

TScan Therapeutics Cash Flow Statement API

Pull TScan Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=TCRX&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY